Aleksandr P. Pechenyi
Research Subjects
Aleksandr P. Pechenyi has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- E. V. Peganova
Regional clinical oncology hospital
2 shared publications - Inna P. Ganshina
Blokhin National Medical Research Center of Oncology
2 shared publications - Ruslan Aleksandrovich Zukov
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
2 shared publications - S. V. Averyanova
Regional Clinical Oncology Dispensary
2 shared publications - A. A. Leonov
Clinical Oncology Dispensary No. 1
1 shared publication A. A. Pryadko
Petrovax LLC
1 shared publication
Latest Publications
- Open Access
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 104-110
Resolution on the results of the expert council on the topic “Expanding options for maintenance therapy of ovarian cancer: the place of the new PARP inhibitor Fuzuloparib in Russian clinical guidelines”
Expert advisory board meetings were held on April 2, 2026, and July 3, 2026, during which the country’s leading oncologists discussed the current state of pharmacological therapy for ovarian cancer and the prospects for introducing a new selective PARP inhibitor, fuzuloparib. The treatment of malignant ovarian neoplasms remains one of the most challenging areas in gynecologic oncology. Although ovarian cancer ranks third in incidence—following endometrial and cervical cancers—it firmly holds the top spot in terms of mortality. Approximately 14,000 new cases are diagnosed annually in Russia, with over 40% of patients diagnosed at advanced stages (III–IV). The advent of PARP inhibitors has fundamentally transformed the maintenance therapy paradigm for BRCA-associated and HRD-positive cancers; however, the availability of this class of drugs in the Russian Federation remains limited, and current practice necessitates an expansion of therapeutic options.
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 104-110
Open AccessResolution on the results of the expert council on the topic “Expanding options for maintenance therapy of ovarian cancer: the place of the new PARP inhibitor Fuzuloparib in Russian clinical guidelines”
Expert advisory board meetings were held on April 2, 2026, and July 3, 2026, during which the country’s leading oncologists discussed the current state of pharmacological therapy for ovarian cancer and the prospects for introducing a new selective PARP inhibitor, fuzuloparib. The treatment of malignant ovarian neoplasms remains one of the most challenging areas in gynecologic oncology. Although ovarian cancer ranks third in incidence—following endometrial and cervical cancers—it firmly holds the top spot in terms of mortality. Approximately 14,000 new cases are diagnosed annually in Russia, with over 40% of patients diagnosed at advanced stages (III–IV). The advent of PARP inhibitors has fundamentally transformed the maintenance therapy paradigm for BRCA-associated and HRD-positive cancers; however, the availability of this class of drugs in the Russian Federation remains limited, and current practice necessitates an expansion of therapeutic options.
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 30-36
Ribociclib as a key component of highly effective endocrine therapy regimens of early lines in metastatic HR+ HER2- breast cancer: A series of real-world clinical cases from the Russian Federation
The treatment of metastatic HR+ Her2neu negative breast cancer (BC) is a challenging clinical task that required in-depth study of oncogenesis and the development of several new classes of drugs, which significantly changed the therapeutic arsenal. The results of the MONALEESA-2, -3, and -7 studies demonstrated the efficacy of the combination of ribociclib with endocrine therapy in this cohort of patients, leading to clinically and statistically significant increases in progression-free and overall survival, including in patients with adverse prognostic factors. The results of real-world clinical practice were no less optimistic, as demonstrated by the presented clinical cases. The paper presents three clinical cases of patients with metastatic HR+/HER2- BC in whom ribociclib-based combination therapy provided an unusually long control of the disease. Clinical case 1. A 42-year-old female patient with luminal B HER2- BC and multiple bone metastases received ribociclib in combination with letrozole after ovariectomy. During therapy, a complete metabolic response was achieved, which persisted for more than 97 months. The adverse events were limited to a manageable grade 1 arrhythmia and a neutropenia episode. Clinical case 2. A 70-year-old female patient with late recurrence of BC and metastatic lesions of lymph nodes and bones received ribociclib in combination with letrozole in first-line therapy. Sustained regression of lymphadenopathy and stabilization of bone lesions with a disease control duration of 72 months were achieved. No toxicity was reported, and no dose reduction was required. Clinical case 3. A 64-year-old female patient with visceral and bone metastases and a PIK3CA mutation received ribociclib + fulvestrant in the second-line therapy. Long-term stabilization was achieved within 6.5 years with minimal toxicity. Progression required a change in therapy regimen. The presented cases demonstrate the possibility of long-term control of metastatic HR+/HER2- BC with ribociclib in combination with endocrine therapy, confirming the importance of molecular-specific therapy selection and the potential of an individualized approach in clinical practice.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 30-36
Open AccessRibociclib as a key component of highly effective endocrine therapy regimens of early lines in metastatic HR+ HER2- breast cancer: A series of real-world clinical cases from the Russian Federation
The treatment of metastatic HR+ Her2neu negative breast cancer (BC) is a challenging clinical task that required in-depth study of oncogenesis and the development of several new classes of drugs, which significantly changed the therapeutic arsenal. The results of the MONALEESA-2, -3, and -7 studies demonstrated the efficacy of the combination of ribociclib with endocrine therapy in this cohort of patients, leading to clinically and statistically significant increases in progression-free and overall survival, including in patients with adverse prognostic factors. The results of real-world clinical practice were no less optimistic, as demonstrated by the presented clinical cases. The paper presents three clinical cases of patients with metastatic HR+/HER2- BC in whom ribociclib-based combination therapy provided an unusually long control of the disease. Clinical case 1. A 42-year-old female patient with luminal B HER2- BC and multiple bone metastases received ribociclib in combination with letrozole after ovariectomy. During therapy, a complete metabolic response was achieved, which persisted for more than 97 months. The adverse events were limited to a manageable grade 1 arrhythmia and a neutropenia episode. Clinical case 2. A 70-year-old female patient with late recurrence of BC and metastatic lesions of lymph nodes and bones received ribociclib in combination with letrozole in first-line therapy. Sustained regression of lymphadenopathy and stabilization of bone lesions with a disease control duration of 72 months were achieved. No toxicity was reported, and no dose reduction was required. Clinical case 3. A 64-year-old female patient with visceral and bone metastases and a PIK3CA mutation received ribociclib + fulvestrant in the second-line therapy. Long-term stabilization was achieved within 6.5 years with minimal toxicity. Progression required a change in therapy regimen. The presented cases demonstrate the possibility of long-term control of metastatic HR+/HER2- BC with ribociclib in combination with endocrine therapy, confirming the importance of molecular-specific therapy selection and the potential of an individualized approach in clinical practice.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 17-24
Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice
Introduction. Advances in molecular biology and biotechnology have enhanced the understanding of triple-negative breast cancer (TNBC) biology and facilitated the identification of patient subgroups that may potentially benefit from novel therapeutic approaches.Objective. The aim of this study is to evaluate the efficacy of the combination of atezolizumab and nab-paclitaxel in patients with locallyadvanced/metastatic TNBC in real-world clinical practice in the Russian Federation.Methods. This retrospective multicenter study included 65 patients with metastatic TNBC who received the atezolizumab and nab-paclitaxel in the second line of treatment and patients with early progression following neoadjuvant/adjuvant chemotherapy (≤12 months, primary resistance population) from October 2019 to September 2023 in routine clinical practice.Results. At the median follow-up of 11.5 months the median progression-free survival (mPFS) was 11.43 months (95 % CI, 6.59–16.28) in the ITT population. There was only factor associated with worsened mPFS – recurrence-free interval of ≤12 months following anthracycline/taxane-based neoadjuvant/adjuvant chemotherapy. mPFS was 15.8 months for primary metastatic or anthracycline/taxane-sensitive TNBC vs. 6.4 months for primary resistance population (OR 0.52, 95 % CI 0.54–0.97; p=0.03). A trend towards improved PFS was observed in the BRCA1/2 wt subgroup and patients with objective response. The mPFS for BRCA1/2 wt patients was 13.9 months vs. 5.6 months for BRCA1/2 mut patients (p=0.14). mPFS in patients with an objective response was 21.9 months vs 13.9 months in those without an objective response (p=0.63).Conclusions. This analysis represents the first multicenter study evaluating the efficacy of the combination of atezolizumab and nab-paclitaxel in real-world clinical practice in Russian population. The combination allows for an objective response rate of 20 % and mPFS of 11.43 months for patients as in the second line of treatment as with primary resistance.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 17-24
Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice
Introduction. Advances in molecular biology and biotechnology have enhanced the understanding of triple-negative breast cancer (TNBC) biology and facilitated the identification of patient subgroups that may potentially benefit from novel therapeutic approaches.Objective. The aim of this study is to evaluate the efficacy of the combination of atezolizumab and nab-paclitaxel in patients with locallyadvanced/metastatic TNBC in real-world clinical practice in the Russian Federation.Methods. This retrospective multicenter study included 65 patients with metastatic TNBC who received the atezolizumab and nab-paclitaxel in the second line of treatment and patients with early progression following neoadjuvant/adjuvant chemotherapy (≤12 months, primary resistance population) from October 2019 to September 2023 in routine clinical practice.Results. At the median follow-up of 11.5 months the median progression-free survival (mPFS) was 11.43 months (95 % CI, 6.59–16.28) in the ITT population. There was only factor associated with worsened mPFS – recurrence-free interval of ≤12 months following anthracycline/taxane-based neoadjuvant/adjuvant chemotherapy. mPFS was 15.8 months for primary metastatic or anthracycline/taxane-sensitive TNBC vs. 6.4 months for primary resistance population (OR 0.52, 95 % CI 0.54–0.97; p=0.03). A trend towards improved PFS was observed in the BRCA1/2 wt subgroup and patients with objective response. The mPFS for BRCA1/2 wt patients was 13.9 months vs. 5.6 months for BRCA1/2 mut patients (p=0.14). mPFS in patients with an objective response was 21.9 months vs 13.9 months in those without an objective response (p=0.63).Conclusions. This analysis represents the first multicenter study evaluating the efficacy of the combination of atezolizumab and nab-paclitaxel in real-world clinical practice in Russian population. The combination allows for an objective response rate of 20 % and mPFS of 11.43 months for patients as in the second line of treatment as with primary resistance.